AACR Annual Meeting
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Related Articles
FDA Approves Larotrectinib for NTRK-Positive Solid Tumors
The FDA has granted full approval to larotrectinib for select patients with solid tumors harboring a NTRK gene fusion.
Intravenous Sirolimus Shows Tolerability, Early Efficacy in Malignant PEComa
Phase 1b data support further exploration of intravenous sirolimus in patients with malignant PEComa.
Expanded FDA Approval Broadens the Role of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC
Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.
Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC
Osimertinib plus Dato-DXd elicits responses in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib.
Dr Jacob on the Potential for TAR-200 to Shift the Treatment Paradigm in NMIBC
Joseph Jacob, MD, MCR, discusses how emerging data for TAR-200 could represent a shift in the treatment paradigm for patients with high-risk non–muscle-invasive bladder cancer.
Insights Into Marginal Zone Lymphoma
Catherine Thieblemont, MD, PhD, and Paola Ghione, MD, MSEpi, discuss insights into marginal zone lymphoma.
Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer
Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing, the use…
Revisit Every OncLive On Air Episode From April 2025
Read a recap of the episodes of OncLive On Air that aired in April 2025.
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Dr. Benjamin Weinberg presents findings from a ctDNA-based analysis of the CALGB/SWOG 80702 trial, showing that circulating tumor DNA status may help identify patients with…
Responsible AI Use Ushers in a New Era of Oncology Practice and Patient Care
Douglas Flora, MD, FACCC, LSSBB, discusses the growing role of artificial intelligence tools in oncology practice.